Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18886396 | APOPTOTIC CELL MIMIC | September 2024 | April 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18797746 | BIOMARKER FOR PREDICTING DRUG RESISTANCE OF BRUTON'S TYROSINE KINASE INHIBITORS AND APPLICATION THEREOF | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18608025 | APOPTOTIC CELL MIMIC | March 2024 | August 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18507183 | FACTOR XII (F12) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | November 2023 | February 2024 | Allow | 4 | 0 | 0 | No | No |
| 18487302 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | October 2023 | March 2025 | Allow | 17 | 1 | 0 | No | No |
| 18239189 | SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT | August 2023 | April 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18234952 | METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) | August 2023 | April 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18231434 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | August 2023 | January 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18218155 | FACTOR XII (HAGEMAN FACTOR) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), AND KININOGEN 1 (KNG1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | July 2023 | February 2025 | Allow | 20 | 1 | 1 | No | No |
| 18215848 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | June 2023 | January 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18334932 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | June 2023 | December 2023 | Allow | 6 | 1 | 0 | No | No |
| 18131509 | METHODS OF TREATING OSMIDROSIS | April 2023 | December 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18180179 | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | March 2023 | March 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18116903 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | March 2023 | November 2024 | Abandon | 20 | 0 | 1 | No | No |
| 18172707 | OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION | February 2023 | November 2024 | Allow | 21 | 1 | 1 | No | No |
| 18150381 | MODULATION OF FACTOR 11 EXPRESSION | January 2023 | May 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18088395 | C/EBP Alpha Short Activating RNA Compositions and Methods of Use | December 2022 | May 2025 | Abandon | 28 | 2 | 0 | No | No |
| 18069123 | COMPOSITIONS AND METHODS FOR PREPARING CAPPED MRNA | December 2022 | October 2023 | Allow | 10 | 2 | 0 | Yes | No |
| 18063972 | Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis | December 2022 | August 2023 | Allow | 8 | 3 | 0 | Yes | No |
| 18064086 | Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis | December 2022 | August 2023 | Allow | 8 | 2 | 0 | Yes | No |
| 18060990 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | December 2022 | July 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18071424 | METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHA | November 2022 | May 2025 | Abandon | 30 | 2 | 0 | No | No |
| 18056929 | REAGENTS FOR TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION AND USE THEREOF | November 2022 | January 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18055597 | USE OF PI3KC2B INHIBITORS FOR THE PRESERVATION OF VASCULAR ENDOTHELIAL CELL BARRIER INTEGRITY | November 2022 | August 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17987064 | METHODS FOR TREATING HYPERCHOLESTEROLEMIA | November 2022 | December 2024 | Abandon | 25 | 1 | 0 | No | No |
| 18049378 | GAMMA HERPESVIRUS CIRCULAR RNA | October 2022 | December 2024 | Abandon | 26 | 2 | 1 | No | No |
| 17963962 | METHOD FOR ENHANCING RECOVERY OF COSMETIC LASER-TREATED SKIN | October 2022 | November 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17936258 | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | September 2022 | August 2024 | Allow | 22 | 1 | 0 | No | No |
| 17931270 | HIPPO AND DYSTROPHIN COMPLEX SIGNALING IN CARDIOMYOCYTE RENEWAL | September 2022 | January 2024 | Allow | 16 | 1 | 0 | No | No |
| 17893742 | IN VITRO TRANSCRIPTION TECHNOLOGIES | August 2022 | January 2025 | Allow | 29 | 2 | 0 | Yes | No |
| 17817303 | NOVEL PRECURSOR MIRNA AND APPLICATION THEREOF IN TUMOR TREATMENT | August 2022 | September 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17816087 | MICRORNA ASSAY FOR DETECTION AND MANAGEMENT OF PANCREATIC CANCER PRECURSORS | July 2022 | June 2024 | Allow | 23 | 2 | 0 | No | No |
| 17813493 | p63 INACTIVATION FOR THE TREATMENT OF HEART FAILURE | July 2022 | February 2024 | Allow | 19 | 1 | 0 | No | No |
| 17867260 | siRNA-Copolymer Compositions And Methods Of Use For Treatment Of Liver Cancer | July 2022 | August 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17855851 | ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | July 2022 | August 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17843162 | METHOD FOR PREPARING MRNA-GALNAC TARGETING MOLECULE, IN VIVO DELIVERY SYSTEM THEREFOR, AND USE THEREOF | June 2022 | March 2024 | Abandon | 21 | 2 | 1 | Yes | No |
| 17834762 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING ENDOMETRIOSIS | June 2022 | March 2023 | Abandon | 9 | 0 | 1 | No | No |
| 17740066 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION | May 2022 | January 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17661803 | SIRNA STRUCTURES FOR HIGH ACTIVITY AND REDUCED OFF TARGET | May 2022 | November 2023 | Allow | 18 | 1 | 0 | No | No |
| 17723555 | COMPOSITIONS AND METHODS FOR DISRUPTING THE MOLECULAR MECHANISMS ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION AND NEURODEGENERATIVE DISEASE | April 2022 | February 2024 | Allow | 22 | 2 | 1 | No | No |
| 17721666 | METHODS AND COMPOSITIONS FOR TREATING ATHEROSCLEROSIS | April 2022 | March 2025 | Abandon | 35 | 4 | 0 | No | No |
| 17714717 | Materials And Methods Of Treating MHC-1-Opathy Risk Haplotypes | April 2022 | March 2025 | Allow | 36 | 2 | 1 | No | No |
| 17714730 | Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof | April 2022 | May 2025 | Abandon | 37 | 2 | 0 | No | Yes |
| 17712766 | Selective Antisense Compounds and Uses Thereof | April 2022 | January 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17766153 | CHEMICAL MODIFICATIONS OF SMALL INTERFERING RNA WITH MINIMAL FLUORINE CONTENT | April 2022 | April 2025 | Allow | 36 | 0 | 0 | No | No |
| 17700339 | METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE | March 2022 | February 2024 | Abandon | 23 | 0 | 1 | No | No |
| 17697685 | MODIFIED iRNA AGENTS | March 2022 | September 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17586850 | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | January 2022 | May 2025 | Allow | 40 | 2 | 1 | Yes | No |
| 17584463 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES | January 2022 | March 2024 | Allow | 26 | 1 | 0 | No | No |
| 17581089 | OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION | January 2022 | August 2023 | Allow | 19 | 1 | 0 | No | No |
| 17575410 | METHODS TO DETECT MOTOR NEURON DISEASE COMPRISING MICRO-RNAs | January 2022 | August 2024 | Allow | 31 | 3 | 0 | No | No |
| 17554476 | MICRORNA ASSAY FOR DETECTION AND MANAGEMENT OF PANCREATIC CANCER PRECURSORS | December 2021 | June 2025 | Allow | 41 | 4 | 1 | Yes | No |
| 17554920 | COMPOUNDS AND METHODS FOR MODULATING FACTOR XII | December 2021 | December 2023 | Allow | 24 | 0 | 2 | No | No |
| 17453950 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | November 2021 | January 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17517006 | ANTISENSE NUCLEIC ACIDS | November 2021 | March 2024 | Allow | 29 | 1 | 1 | No | No |
| 17494751 | STABILIZED POLYRIBONUCLEOTIDE CODING FOR AN ELASTIC FIBROUS PROTEIN | October 2021 | March 2025 | Allow | 41 | 4 | 0 | No | Yes |
| 17494039 | SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT | October 2021 | October 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17487019 | METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) | September 2021 | October 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17472413 | CONTROL OF INSECT INFESTATION | September 2021 | November 2023 | Allow | 26 | 1 | 1 | No | No |
| 17464871 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | September 2021 | August 2023 | Abandon | 23 | 0 | 1 | No | No |
| 17402081 | DOUBLE-STRANDED OLIGO RNA STRUCTURE COMPRISING miRNA | August 2021 | November 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17398923 | REVERSIR TM COMPOUNDS | August 2021 | October 2024 | Allow | 38 | 3 | 0 | Yes | No |
| 17393738 | Compositions for Modulating Ataxin 2 Expression | August 2021 | July 2023 | Allow | 24 | 1 | 0 | No | No |
| 17443813 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF PROTEIN C (PROC) GENES | July 2021 | July 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17373361 | siRNA/Nanoparticle Formulations for Treatment of Middle-East Respiratory Syndrome Coronaviral Infection | July 2021 | July 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17372710 | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | July 2021 | August 2023 | Allow | 26 | 2 | 1 | No | No |
| 17304402 | siRNA Inhibition Of Human Antigen R Expression For Treatment of Cancer | June 2021 | January 2024 | Abandon | 30 | 2 | 0 | No | No |
| 17350114 | COMPOSITIONS AND METHODS FOR TREATING COVID-19 | June 2021 | September 2024 | Abandon | 39 | 1 | 1 | No | No |
| 17306908 | RNA DRUGS AND METHOD OF TREATING AGE-RELATED DISEASE | June 2021 | March 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17327469 | ALLELE SPECIFIC MODULATORS OF P23H RHODOPSIN | May 2021 | April 2023 | Allow | 23 | 1 | 0 | No | No |
| 17317688 | METHOD AND MEANS TO DELIVER miRNA TO TARGET CELLS | May 2021 | July 2025 | Abandon | 50 | 2 | 1 | Yes | No |
| 17306929 | COMPOSITIONS AND METHODS FOR PREVENTION OF BLADDER FIBROSIS | May 2021 | January 2024 | Allow | 32 | 3 | 0 | No | No |
| 17240659 | INHIBITION OF OXIDATIVE STRESS IN ATRIAL FIBRILLATION | April 2021 | May 2023 | Allow | 25 | 1 | 0 | Yes | No |
| 17238773 | METHODS AND COMPOSITIONS FOR INCREASING THE SUPPRESSIVE FUNCTION OF REGULATORY T-CELLS (TREGS) | April 2021 | March 2024 | Abandon | 35 | 2 | 1 | No | No |
| 17286655 | MODIFIED NUCLEIC ACID HAVING IMPROVED TREATMENT EFFICACY, AND ANTICANCER PHARMACEUTICAL COMPOSITION CONTAINING SAME | April 2021 | June 2025 | Allow | 50 | 2 | 1 | No | No |
| 17219974 | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | April 2021 | October 2023 | Abandon | 30 | 1 | 1 | No | No |
| 17186078 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | February 2021 | March 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17268206 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | February 2021 | January 2024 | Allow | 35 | 2 | 1 | No | No |
| 17268324 | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | February 2021 | July 2022 | Allow | 17 | 1 | 0 | No | No |
| 17172461 | PROGRAMMABLE CONDITIONAL SIRNAS AND USES THEREOF | February 2021 | February 2024 | Allow | 36 | 2 | 1 | No | No |
| 17161456 | MYC NUCLEIC ACIDS AND USES THEREOF | January 2021 | August 2023 | Abandon | 31 | 2 | 0 | No | No |
| 17132803 | OLIGONUCLEOTIDES FOR TISSUE SPECIFIC GENE EXPRESSION MODULATION | December 2020 | February 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17131600 | ADIPOCYTE-TARGETING DNA NANODRUG AND PREPARATION AND USES THEREOF | December 2020 | August 2023 | Allow | 32 | 1 | 1 | No | No |
| 17254421 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | December 2020 | July 2023 | Abandon | 31 | 0 | 1 | No | No |
| 17124780 | TREATMENT AND PREVENTION OF VIRAL INFECTION | December 2020 | March 2023 | Abandon | 27 | 2 | 0 | No | No |
| 17124066 | REAGENTS FOR TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION AND USE THEREOF | December 2020 | June 2023 | Abandon | 30 | 2 | 0 | No | No |
| 17121858 | Factor XII (Hageman Factor) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | December 2020 | August 2023 | Abandon | 32 | 1 | 1 | No | No |
| 16972152 | USE OF PI3KC2B INHIBITORS FOR THE PRESERVATION OF VASCULAR ENDOTHELIAL CELL BARRIER INTEGRITY | December 2020 | November 2022 | Allow | 23 | 2 | 1 | No | No |
| 17110248 | ENDOMUCIN INHIBITOR AS AN ANTI-ANGIOGENIC AGENT | December 2020 | January 2023 | Allow | 26 | 1 | 0 | No | No |
| 17059949 | GAMMA HERPESVIRUS CIRCULAR RNA | November 2020 | July 2022 | Allow | 20 | 1 | 1 | No | No |
| 17102787 | METHODS AND COMPOSITIONS FOR REDUCING IMMUNOSUPRESSION BY TUMOR CELLS | November 2020 | October 2022 | Allow | 22 | 1 | 0 | No | No |
| 16950413 | Methods and Pharmaceutical Compositions for Treating Lymphoid Malignancy | November 2020 | December 2023 | Allow | 37 | 2 | 0 | Yes | Yes |
| 16950395 | USE OF MIR101 OR MIR128 IN THE TREATMENT OF SEIZURE DISORDERS | November 2020 | May 2023 | Allow | 30 | 3 | 0 | No | No |
| 17055523 | CODON-OPTIMIZED ACID ALPHA-GLUCOSIDASE EXPRESSION CASSETTES AND METHODS OF USING SAME | November 2020 | May 2024 | Allow | 42 | 1 | 1 | No | No |
| 17096260 | HIPPO AND DYSTROPHIN COMPLEX SIGNALING IN CARDIOMYOCYTE RENEWAL | November 2020 | May 2022 | Allow | 18 | 1 | 0 | No | No |
| 17053615 | HEXAMERIC TETRAHEDRAL RNA NANOSTRUCTURES | November 2020 | March 2023 | Allow | 28 | 2 | 1 | Yes | No |
| 17079699 | SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT | October 2020 | October 2021 | Abandon | 11 | 2 | 0 | No | No |
| 17069931 | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | October 2020 | March 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17069926 | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) | October 2020 | August 2022 | Abandon | 22 | 1 | 0 | No | No |
| 17069711 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION | October 2020 | May 2022 | Abandon | 19 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GIBBS, TERRA C.
With a 16.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 15.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GIBBS, TERRA C works in Art Unit 1635 and has examined 926 patent applications in our dataset. With an allowance rate of 51.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner GIBBS, TERRA C's allowance rate of 51.6% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by GIBBS, TERRA C receive 1.84 office actions before reaching final disposition. This places the examiner in the 57% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by GIBBS, TERRA C is 30 months. This places the examiner in the 39% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +25.7% benefit to allowance rate for applications examined by GIBBS, TERRA C. This interview benefit is in the 76% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.1% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 43.5% of cases where such amendments are filed. This entry rate is in the 60% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 85.0% of appeals filed. This is in the 76% percentile among all examiners. Of these withdrawals, 73.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 80.1% are granted (fully or in part). This grant rate is in the 93% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 8.4% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.1% of allowed cases (in the 66% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.